Transforming growth factor-β receptor (TGF-β receptor) (TGFBR (sometimes TGF-βR, with subtypes TGFBR1 and TGFBR2))

The transforming growth factor-β receptor is a transmembrane serine/threonine kinase receptor activated by TGF-β superfamily cytokines. It operates as a heteromeric complex, typically involving TGFBR2 (type II, constitutively active kinase) and TGFBR1 (type I, also known as ALK5), which together propagate intracellular signaling mainly through reversible phosphorylation of receptor-regulated SMAD transcription factors (SMAD2/3). This canonical pathway transmits signals that regulate cell proliferation, differentiation, extracellular matrix production, immune responses, and apoptosis. Dysregulation of TGF-β receptor signaling is implicated in a wide range of diseases, including cancer (acting as both tumor suppressor and promoter depending on cellular context), tissue fibrosis, inflammatory and autoimmune diseases, and some cardiovascular and neurodegenerative conditions. TGF-β pathway inhibitors are under intense investigation as therapeutic agents for both fibrosis and oncology indications, leveraging a variety of strategies such as small molecule kinase inhibitors, ligand traps, and monoclonal antibodies[1][2][3][4][5][7].

Other names

TGF-beta receptorTGFBR1 (ALK5)TGFBR2Transforming growth factor beta receptorTGF-β serine/threonine kinase receptor

Small molecule inhibition of receptor kinase activity; Neutralizing antibodies blocking ligand-receptor binding; Ligand traps sequestering TGF-β ligands; Antisense oligonucleotides suppressing TGF-β or receptor expression.